BioCentury
ARTICLE | Company News

Bayer, Roche deal

January 23, 2012 8:00 AM UTC

Roche's Ventana Medical Systems Inc. tissue diagnostic unit will develop, manufacture and commercialize a companion diagnostic to identify patients most likely to benefit from an undisclosed, cancer antibody-drug conjugate (ADC) from Bayer. Ventana's immunohistochemistry platform will be used for patient selection in clinical trials by analyzing the expression level of undisclosed tumor targets. The partners may begin projects to develop diagnostic tests for additional targeted cancer therapies under the initial five-year deal. Terms were not disclosed. ...